Möchten Sie immer auf dem neuesten Stand bleiben?

NEW YORK, April 02, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell...

Candidate has potential to be a first-in-class treatment offering biologic-like disease control from an oral small moleculeRegulatory submission preparation and entry into the clinic is expected in H1...

MGH collaboration to evaluate TRE-515 in ALS patients, advancing development of a first-in-class therapy targeting inflammation and nucleotide metabolism.

ARDS / hypoxemic pneumonia Phase 2 trial initiation 1H 2026; early data by year end; market opportunity of ~200,000–300,000 patients annually in US/EUC-Further Consortium collaboration adds to growing...

Featured presentation highlights positive BroADen Phase 1b atopic dermatitis trial results supporting KT-621’s compelling oral profile Parallel Phase 2b trials, BROADEN2 in atopic dermatitis and...

- Proposed acquisition strengthens Novartis immunology strategy in food allergy and other IgE-driven diseases   - Lead asset Exl-111 builds on proven IgE biology with a differentiated mechanism...

Anaveon, a late-stage biotech company, appoints Thaminda Ramanayake as its new Chief Executive Officer.

Vista, CA, March 18, 2026 (GLOBE NEWSWIRE) -- Mindera Health, a leader in precision medicine for dermatological conditions, and Mountaineer Biosciences today announced the launch of Subtilitas, a...

Mestag Therapeutics Announces $40 Million Financing and Appoints Chief Medical Officer and Chief Development Officer in Preparation to Enter the Clinic

Commit Biologics appoints seasoned biotech entrepreneur Thomas L. F. Montgomery Andresen, PhD, as Chief Executive Officer.